BIOCAD opposes registration of drug sets
[PharmVestnik # 4, 09/02/2016, p. 1, cont’d p. 3]
R-Pharm led the development of a road map for a new market segment
At the end of January, the experts discussed a road map of the HealthNet (National Technological Expertise) on the Open Government site. This is a so far unshaped healthcare market that is globally to exceed 100 bn USD by 2035. It is worth noting that the road map workgroup is led by R-Pharm Chairman of the Board Alexey Repik.
[PharmVestnik # 4, 09/02/2016, p. 2]
“One needs to combine calculated risks with sound economy”
The year 2015 was abundant in the legislative changes concerning API manufacture. The relevant ministries were quite careful when developing the local manufacturer support mechanisms, which naturally affected the industry development. Many companies, despite the tough economic situation, saw this fact as an opportunity to build up their production potential and broaden their market presence. Within the framework of the “Editorial Fireplace” rubric, President and co-owner of Active Component Co. Alexander SEMYONOV told about the corporate strategy changes in the new conditions as well as trends prevailing in the Pharma market.
[PharmVestnik # 4, 09/02/2016, p. 4]
Ministry of Health is “twice shy”
MoH’s overvigilance torpedoes amendments to the price margin registry
The Association of International Pharmaceutical Manufacturers (AIPM) approached the Russian Government with a letter in which pharmaceutical companies ask for help in overcoming the controversy between the MoH and the Federal Antimonopoly Service (FAS). The meat of the issue is as follows: if a company wishes to make changes in the price margin registry regarding a manufacturing site, the MoH forwards the documents to the FAS for approval of a maximum sale price. However, the FAS sends the documents back as the maximum price does not change in this case and, consequently, there is no need for approval. As a result, manufacturers cannot release their drugs to the market.
[PharmVestnik # 4, 09/02/2016, p. 5]
Zika virus close on swine flu heels
For nearly a month, swine flu keeps all Russian regions on their toes. Thousands of educational facilities are placed under quarantine; all antivirals and medical face masks fly off the pharmacy shelves. Since the end of January, Zika virus has been trying to share spotlight with the H1N1 flu. The former has already been declared a global threat by the WHO. In turn, Russia’s MoH does not consider either the swine flu epidemics or Zika’s rapid proliferation to be anything extraordinary for this country and calls for calm.
[PharmVestnik # 4, 09/02/2016, p. 6]
Some experts suggest that companies pay closer attention to their respective sectors
This year’s first meeting of the Russian Association of Pharmaceutical Marketing (RAPM) held on January 28, differed substantially from similar meetings of the club members notwithstanding the agenda traditional for this period, i.e. summing up the results of the previous year. The speakers were frankly negative in their attitudes when discussing the results of 2015 and making forecasts for 2016.
[PharmVestnik # 4, 09/02/2016, pp. 8-9]
No limits for cohesion
Russian Pharma market goes through the biggest retail consolidation wave
Already in early 2016, pharmacy chain Raduga’s new acquisitions were reported. According to PharmVestnik, pharmacy chains Apteka Avicenna (Irkutsk), Gubernskie Apteki (Krasnoyarsk), Info-Medica (part of Larets Zdorovya Group, Novosibirsk), and Farmada (Sochi) joined Raduga Group. Tvoy Doctor and Pharmakopeika chains have unveiled their consolidation plans. The interviews that make the basis for this publication aim at finding out for how long pharmacy consolidation may last and whether independent pharmacies are likely to survive as a result. Another important issue is to come to know what kind of association is more promising – federal or regional.
[PharmVestnik # 4, 09/02/2016, p. 11]
Saving on printed media
Specialized media advertisement market, Q1-315
As of the first three quarters of 2015, a year-on-year decrease in the advertising costs and the number of ad artworks placed in specialized pharmaceutical and medical media was reported. The ad market decreased by 7% in rubles and 16% in the number of artworks placed.
[PharmVestnik # 4, 09/02/2016, p. 12]
Health colonies
Market report: drugs and dietary supplements correcting intestinal microflora, January—November 2014 — January—November 2015
Any human organism is colonized by multiple microorganisms. Most of them, the so-called beneficial bacteria, are necessary for the organism to function properly. However, under the impact of external factors, the number of bacteria may reduce, which may lead to adverse outcomes.
[PharmVestnik # 4, 09/02/2016, p. 13]
Transferring from import substitution to export oriented model
The editor-in-chief of PharmVestnik newspaper, website, and TV visited a regular Stamegna-sponsored event in Milan, Italy, and decided to share his ideas and observations regarding differences in strategies of the European and Russian parapharmaceutical manufacturers.
[PharmVestnik # 4, 09/02/2016, p. 14]
Between business and the government
Realia of pharmaceutical and medical activities in Kazakhstan
Atameken, the National Chamber of Kazakhstan Entrepreneurs, is a nonprofit organization founded in September 2013 in order to reinforce the power of businesses when negotiating with the government and state authorities. Atameken’s major objective is protecting the rights and interests of businesses and providing for a broad involvement of entrepreneurs into the legislation development process regarding the operating rules for businesses. One of Atameken committees deals with healthcare. Atameken Deputy Chairwoman of the Board Julia YAKUPBAEVA told PharmVestnik how the National Chamber of Kazakhstan Entrepreneurs operated.
[PharmVestnik # 4, 09/02/2016, p. 16]
Federal group to test a new partnership type with regional retailers
ROSTA Group signed a marketing agreement with regional pharmacy chain Farmada uniting more than 30 pharmacies in Sochi region. According to a Farmada representative, as of January, an economic effect from such partnership is already evident. However, experts believe that such alliance is nothing more than getting ready for merger.
[PharmVestnik # 4, 09/02/2016, p. 17]
Botulotoxin to treat cardiac arrythmia
In Novosibirsk, preclinical trials of a potentially breakthrough cardiac surgery drug are nearing completion. Physicians expect this drug to be implemented in clinical practice. The drug based on the strongest poison may help avoid arrhythmia during surgical operations and treat this heart disease in many patients.
[PharmVestnik # 4, 09/02/2016, p. 17]
